Neuroendocrine Tumours Treatment Market Report and Forecast 2025-2034

Neuroendocrine Tumours Treatment Market Size

The neuroendocrine tumours treatment market was valued at USD 2.45 billion in 2024, driven by the rising incidence of neuroendocrine tumours and advancements in treatment modalities across the 8 major markets. The market is expected to grow at a CAGR of 8.23% during the forecast period of 2025-2034, with the values likely to reach USD 4.30 billion by 2034.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Neuroendocrine Tumours Treatment Market Outlook

• There is a rising incidence of neuroendocrine tumours globally. The improved diagnostic capabilities and awareness among healthcare providers have led to more frequent detection and diagnosis of NETs. This trend is expected to drive market growth as more patients seek treatment.

• The treatment landscape for neuroendocrine tumours has seen considerable advancements. Targeted therapies such as somatostatin analogs, peptide receptor radionuclide therapy (PRRT), and molecularly targeted agents have demonstrated efficacy in managing NETs. These treatments offer improved outcomes and quality of life for patients, thereby increasing their adoption and contributing to market growth.

• There is ongoing research focused on understanding the underlying biology of neuroendocrine tumours and developing novel therapeutic approaches. Continued innovation in R&D is expected to expand treatment options and further drive market growth.

Neuroendocrine Tumours Treatment Market Overview

Neuroendocrine tumours (NETs) are a diverse group of neoplasms that arise from cells of the neuroendocrine system. These cells are found throughout the body, particularly in organs such as the gastrointestinal tract, pancreas, and lungs. Neuroendocrine cells are specialized cells that have characteristics of both nerve cells (neurons) and hormone-producing cells (endocrine cells). They produce hormones and release them into the bloodstream in response to signals from the nervous system.

The market for neuroendocrine tumours treatment has been growing steadily due to rising incidence rates globally and improved diagnostic capabilities. NETs are considered rare, but their recognition and diagnosis have been increasing, leading to a growing patient pool seeking treatment. The treatment options for NETs include surgery, chemotherapy, targeted therapy (such as somatostatin analogs and mTOR inhibitors), peptide receptor radionuclide therapy (PRRT), and others. The treatment market is driven by the increasing incidence of NETs, growing awareness among healthcare providers and patients, advancements in personalized medicine approaches, and ongoing clinical trials evaluating new therapies and combinations and driving the market growth.

Neuroendocrine Tumours Treatment Market Growth Drivers

Increasing Incidence and Awareness

As awareness about neuroendocrine tumours increase among healthcare providers and the general population, the scope of early detection is higher. Early detection is critical because NETs are often slow-growing and may not cause symptoms until they reach an advanced stage. Improved early detection leads to earlier intervention and treatment, which can potentially improve patient outcomes and survival rates.

There has been a documented increase in the incidence of neuroendocrine tumours globally. This increase is partly due to improvements in diagnostic techniques and surveillance, which have led to better recognition and reporting of NETs cases. Cancer Australia reported that 1 in 55 people were at risk of being diagnosed with neuroendocrine tumours by the age of 85 (1 in 52 for males and 1 in 58 for females) in 2022. As the number of diagnosed cases rises, there is a corresponding increase in the demand for treatment options and thus augmenting the market growth.

Expanding Treatment Options is Expected to Propel Neuroendocrine Tumours Treatment Market Demand

The treatment landscape for NETs has expanded with the introduction of targeted therapies such as somatostatin analogues, mTOR inhibitors, and peptide receptor radionuclide therapy (PRRT). These therapies offer more effective options compared to traditional chemotherapy, driving market growth as they become the standard of care in many regions.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Neuroendocrine Tumours Treatment Market Trends

The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:

Neuroendocrine Tumours Treatment Market Segmentation

Market Breakup by Treatment
 

• Targeted Therapy

• Chemotherapy

• Somatostatin Analogues (SSAs)

• Other

Market Breakup by Route of Administration

• Oral

• Parenteral

Market Breakup by Disease Indication

• Gastrointestinal NET

• Lung NET

• Pancreatic NET

• Others

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
• Japan

• India

Neuroendocrine Tumours Treatment Market Share

Market Segmentation Based on Treatment is Anticipated to Witness Substantial Growth

By treatment, the market is segmented into targeted therapy, chemotherapy, somatostatin analogues (SSAs) and others. The somatostatin analogues (SSAs) segment is dominating the market as somatostatin analogues such as octreotide and lanreotide are effective in controlling symptoms associated with functional NETs, such as carcinoid syndrome. These drugs work by inhibiting the secretion of hormones such as serotonin, histamine, and others, which are responsible for increasing its market share.

Neuroendocrine Tumours Treatment Market Analysis by Region

Based on the region, the market covers the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan and India. The United States is dominating the market share due to increasing technological innovations, along with a relatively high incidence and prevalence of neuroendocrine tumours compared to other regions. Improved diagnostic capabilities, increased awareness among healthcare providers, and enhanced surveillance contribute to the detection of more NET cases. This high disease burden drives the demand for effective treatment options in the region.

EU-4 also holds a high neuroendocrine tumours treatment market value due to its well-established infrastructure, specialized medical centres, and skilled healthcare professionals. The availability of comprehensive oncology services, including state-of-the-art imaging technologies, advanced surgical techniques, and access to clinical trials, supports the diagnosis and treatment of NETs at various stages and thus driving the regional demand.

Additionally, Japan and India are expected to witness substantial market growth, fueled by the growing patient pool suffering from diseases and increasing collaboration and funding initiatives.

Leading Players in the Neuroendocrine Tumours Treatment Market

The key features of the market report include patent analysis, clinical trials analysis, grant analysis, funding and investment analysis and other strategic initiatives by the leading players. The major companies in the market are as follows:

Pfizer Inc.

Pfizer Inc. has been involved in the research and development of treatments for various medical conditions, including neuroendocrine tumors (NETs). Pfizer has a vast portfolio that includes medications for oncology.

Novartis AG

Novartis AG is a pharmaceutical company actively involved in the research and development of treatments for various medical conditions, including neuroendocrine tumors (NETs).

Ipsen Pharma SA

Ipsen Pharma SA is actively involved in the field of neuroendocrine tumors (NETs) treatment through its oncology portfolio. Ipsen has developed and marketed several medications specifically for NETs. One notable example is Somatuline (lanreotide), which is used for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and carcinoid syndrome.

Other key players in the market include Abbvie Inc., AVEO Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, Hutchison MediPharma Limited, Tarveda Therapeutics, Progenics Pharmaceuticals, Inc., and Eli Lilly & Company among others.

Key Highlights of the Report

Key Questions Answered in the Neuroendocrine Tumours Treatment Market Report

• What was the neuroendocrine tumours treatment market value in 2023?
• What is the neuroendocrine tumours treatment market forecast outlook for 2025-2034?
• What are the regional markets covered in the EMR report?
• What is market segmentation based on treatment?
• What is market segmentation based on the route of administration?
• What is market segmentation based on disease indication?
• What are the major factors aiding the neuroendocrine tumours treatment market demand? 
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the major trends influencing the market? 
• What are the market's major drivers, opportunities, and restraints? 
• Which regional market is expected to lead the market share in the forecast period? 
• Which country is expected to experience expedited growth during the forecast period? 
• How does the prevalence of neuroendocrine tumours affect the market landscape?
• How does the growing technological advancements in treatments impact the market size?
• Which disease indication area is expected to have a high market value in the coming years?
• Who are the key players involved in the neuroendocrine tumours treatment market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?